Comment
doi: 10.1016/S1470-2045(18)30367-X.
Epub 2018 May 24.
Ribociclib in premenopausal women with advanced breast cancer
Affiliations
- PMID: 29804904
- DOI: 10.1016/S1470-2045(18)30367-X
Item in Clipboard
Comment
Ribociclib in premenopausal women with advanced breast cancer
Lancet Oncol.
2018 Jul.
No abstract available
Comment on
-
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24. Lancet Oncol. 2018. PMID: 29804902 Clinical Trial.
Similar articles
-
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.Expert Rev Anticancer Ther. 2018 Mar;18(3):201-213. doi: 10.1080/14737140.2018.1435275. Epub 2018 Feb 19. Expert Rev Anticancer Ther. 2018. PMID: 29457921 Review.
-
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21. Breast Cancer Res Treat. 2018. PMID: 29164421 Free PMC article. Clinical Trial.
-
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.Breast Cancer Res Treat. 2018 Feb;167(3):659-669. doi: 10.1007/s10549-017-4523-y. Epub 2017 Oct 22. Breast Cancer Res Treat. 2018. PMID: 29058175 Free PMC article. Clinical Trial.
-
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Expert Rev Clin Pharmacol. 2017. PMID: 28875723 Review.
-
Expanding ribociclib use.Nat Rev Clin Oncol. 2018 Aug;15(8):470-471. doi: 10.1038/s41571-018-0051-x. Nat Rev Clin Oncol. 2018. PMID: 29872179 No abstract available.
Cited by
-
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.MedComm (2020). 2023 May 2;4(3):e261. doi: 10.1002/mco2.261. eCollection 2023 Jun. MedComm (2020). 2023. PMID: 37143582 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
